【财华社讯】复锐医疗科技(01696.HK)公布，自2026年1月1日起，现任执行董事兼董事会主席刘毅由于 集团工作调动关系，将调任为非执行董事，并将辞去主席、提名委员会主席、薪酬委员会成员及授权代 表的职务。 本文源自：财华网 现任执行董事兼首席执行官Lior Moshe DAYAN将出任执行董事、主席、提名委员会主席及授权代表， 并由于集团工作调动关系而不再担任首席执行官职务。 现任集团全球业务总裁Eyal BEN DAVID将出任首席执行官职务，及公司执行董事兼首席财务官李家宏 亦将同时出任联席首席执行官一职。 吴以芳由于工作调动关系，已呈请辞任公司非执行董事；Caroline Xiaokui JIN已获委任为非执行董事， 均自2026年1月1日起生效。 ...

吴以芳先生(吴先生)由于工作调动关系，已呈请辞任公司非执行董事，自2026年1月1日起生效;及 Caroline Xiaokui JIN女士(Jin女士)已获委任为非执行董事，自2026年1月1日起生效。 现任集团全球业务总裁Eyal BEN DAVID先生(Ben David先生)将出任首席执行官职务，及公司执行董事 兼首席财务官李家宏先生(李先生)亦将同时出任公司联席首席执行官一职。 复锐医疗科技(01696)发布公告，自2026年1月1日，现任执行董事兼董事会主席刘毅先生(刘先生)由于集 团工作调动关系，将调任为非执行董事，并将辞去主席、董事会提名委员会主席、董事会薪酬委员会成 员及公司授权代表的职务。刘先生将继续担任提名委员会成员的职务。 现任执行董事兼首席执行官Lior Moshe DAYAN先生(Dayan先生)将出任执行董事、主席、提名委员会主 席及授权代表，并由于集团工作调动关系而不再担任首席执行官职务;现任非执行董事冯蓉丽女士将出 任薪酬委员会成员;及现任独立非执行董事陈志峰先生将出任提名委员会成员。 ...

智通财经APP讯，复锐医疗科技(01696)发布公告，自2026年1月1日， 现任执行董事兼董事会主席刘毅 先生(刘先生)由于集团工作调动关系，将调任为非执行董事，并将辞去主席、董事会提名委员会主席、 董事会薪酬委员会成员及公司授权代表的职务。刘先生将继续担任提名委员会成员的职务。 现任执行董事兼首席执行官Lior Moshe DAYAN先生(Dayan先生)将出任执行董事、主席、提名委员会主 席及授权代表，并由于集团工作调动关系而不再担任首席执行官职务;现任非执行董事冯蓉丽女士将出 任薪酬委员会成员;及现任独立非执行董事陈志峰先生将出任提名委员会成员。 现任集团全球业务总裁Eyal BEN DAVID先生(Ben David先生)将出任首席执行官职务，及公司执行董事 兼首席财务官李家宏先生(李先生)亦将同时出任公司联席首席执行官一职。 吴以芳先生(吴先生)由于工作调动关系，已呈请辞任公司非执行董事，自2026年1月1日起生效;及 Caroline Xiaokui JIN女士(Jin女士)已获委任为非执行董事，自2026年1月1日起生效。 ...

Core Insights - The "2025 Shanghai Most Investment Potential 50 Startups" list was officially announced at the 18th Shanghai International Private Equity Forum (SIPEF) [2] - Selected companies include Wolant, Linding Optics, and Guangmai Medical, among others [2] - The average new equity financing for the listed companies this year is approximately 107 million yuan, with over 70% of the companies in Series A or later financing rounds [2] - Previous listed companies have raised over 165.28 billion yuan, with an average of 2.24 million yuan in new equity financing in the second year [2] - The total new equity financing for the 2024 listed companies reached 2.91 billion yuan, providing strong backing for future financing [2] Group 1 - The event was attended by Zhou Haiying, Deputy Secretary of the Yangpu District Committee and District Mayor, who delivered a speech [8] - The list was released by Jia Mian, Director of the Shanghai Small and Medium Enterprises Development Service Center [8] - The event is part of the "Maker Shanghai 2025" initiative, which includes various organizations collaborating to promote small and medium enterprises [8] Group 2 - This year marks the tenth consecutive year of organizing the "Shanghai Most Investment Potential 50 Startups" evaluation [9] - The listed companies are included in the "Shanghai Key Cultivation Startup Enterprise Database" [9] - Nearly 100 member units from three private equity associations in Shanghai will focus on connecting the listed companies with financial capital [9]

Core Viewpoint - The stock price of HeFu Medical Technology Co., Ltd. has experienced a significant deviation from its fundamentals, with a cumulative increase of over 20% in three consecutive trading days, indicating potential risks for investors [1] Stock Performance Summary - From October 28, 2025, to December 8, 2025, the company's stock closed at the daily limit price on sixteen trading days, with six instances of abnormal price fluctuations and three instances of severe abnormal fluctuations [1] - The cumulative increase in stock price during this period reached 336.83%, with the closing price on December 8 being 29.18 yuan per share, marking a historical peak [1] Market Sentiment and Risks - The recent continuous rise in stock price suggests an overheated market sentiment and irrational speculation, significantly exceeding the growth rates of the industry and the Shanghai Composite Index during the same period [1] - The stock price is now at a level that is markedly higher than the company's fundamentals, posing a risk of a rapid decline at any moment [1]

编辑：小羊 合富中国（ 603122 ）公告，合富医疗科技股份有限公司股票价格于2025年12月4日、12月5日及 12月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%。公司股价累计涨幅已严重偏离基 本面，投资者参与交易可能面临较大风险。 自2025年10月28日至2025年12月8日，公司股票有十六个交易日以涨停价收盘，并6次触及股价异 常波动、3次触及严重异常波动情形，期间累计涨幅高达336.83%。截至12月8日收盘，公司股价为 29.18元/股，处于历史最高位。股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明 显高于同期行业及上证指数涨幅，且严重显著偏离公司基本面，随时存在快速下跌风险。 ...

格隆汇12月8日｜据合富中国公告，合富医疗科技股份有限公司股票价格于2025年12月4日、12月5日及 12月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%。公司股价累计涨幅已严重偏离基本 面，投资者参与交易可能面临较大风险。自2025年10月28日至2025年12月8日，公司股票有十六个交易 日以涨停价收盘，并6次触及股价异常波动、3次触及严重异常波动情形，期间累计涨幅高达336.83%。 截至12月8日收盘，公司股价为29.18元/股，处于历史最高位。股价短期内连续上涨，存在市场情绪过 热、非理性炒作风险，已明显高于同期行业及上证指数涨幅，且严重显著偏离公司基本面，随时存在快 速下跌风险。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2025年12月8日，该公司斥资117.82万港元回购22.5万股 股份，每股回购价5.21-5.25港元。 ...

合富中国再度涨停，5个交易日内录得3个涨停，累计涨幅为25.56%，累计换手率为88.92%。截至9:32， 该股今日成交量1721.14万股，成交金额5.01亿元，换手率4.32%。最新A股总市值达116.15亿元。 龙虎榜数据显示，该股因日跌幅偏离值达7%、日换手率达20%、日振幅值达15%上榜龙虎榜3次，买卖 居前营业部中，营业部席位合计净买入5272.06万元。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.12.05 | 9.99 | 14.95 | 47523.16 | | 2025.12.04 | 4.87 | 21.97 | 20024.81 | | 2025.12.03 | -10.02 | 22.55 | -19828.09 | | 2025.12.02 | 9.98 | 25.13 | 3278.09 | | 2025.12.01 | -2.43 | 21.71 | -5891.31 | | 2025.11.28 | 7.49 | 27.28 | -10229.31 | | 2025.1 ...

Group 1 - The "2025 Science and Technology Investment Conference" held in Hefei showcased over 70 quality enterprises in fields such as new energy, integrated circuits, and advanced equipment, with 12 hard-tech companies presenting their innovations [1][4] - Hefei's innovation ecosystem is highlighted as a high-level cycle of "technology-industry-finance," demonstrating the city's commitment to fostering a vibrant tech industry [1][4] - The event attracted nearly 100 investment professionals from across the country, indicating strong interest and engagement from the investment community in Hefei's tech enterprises [1][3] Group 2 - Hefei Lanyiy Aviation, a participant in the roadshow, focuses on urban air mobility (UAM) and has achieved significant milestones in eVTOL development, including the acceptance of its type certification application by the Civil Aviation Administration of China [2] - Guokexiang Optical aims to miniaturize large scientific devices into desktop models, enhancing accessibility for semiconductor testing and new material research [2] - Other notable companies include Ruishi Medical with its digital PET technology, and Shuduo Optical, which has developed a leading intraoperative fluorescence guidance system [3] Group 3 - The roadshow represents a systematic display of hard-tech achievements and reflects Anhui Province's strategy to convert technological innovation into high-quality economic growth [4][5] - Hefei has established itself as a national strategic science and technology hub, with 13 major scientific facilities and a stable industrial output from emerging industries [4][5] - The collaboration between local government and industry capital is crucial, providing not only initial funding but also long-term strategic support for companies transitioning from technology to market [5]